Purpose: Lennox-Gastaut syndrome (LGS), a rare, severe form of childhood-onset epilepsy, is difficult to control. Rufinamide is indicated for adjunctive treatment of seizures associated with
INTRODUCTION
Lennox-Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1] [2] [3] . Although the etiology of LGS is frequently unknown, the condition is characterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to control [1, 3] . Combinations of antiepileptic drugs (AEDs) have commonly been used in an attempt to achieve seizure control in these patients [1] .
The goal of treatment for LGS is reduction of seizures to the greatest extent possible while limiting adverse events (AEs), ultimately providing the patient with the best possible quality of life [4] . Pharmacotherapies for the treatment of LGS include rufinamide, clobazam, valproate, lamotrigine, topiramate, felbamate, zonisamide, and levetiracetam [5] . Rufinamide, a triazole derivative structurally dissimilar to other AEDs, is indicated for the adjunctive treatment of seizures associated with LGS in pediatric patients 1 year of age and older as well as in adults [6] .
Available pharmacokinetic (PK) and pharmacodynamic (PD) analyses have demonstrated a positive correlation between plasma rufinamide concentrations and improved seizure control, although AEs are also more likely in patients with higher rufinamide plasma concentrations [7] .
A c c e p t e d M a n u s c r i p t
Rufinamide Dosing Considerations
Manuscript FINAL - Confidential 6 In general, rufinamide has a mild side-effect profile and a relatively low potential for drug-drug interactions. The primary clinically relevant drug-drug interaction is with valproate, which substantially decreases the clearance of rufinamide [8] . Decreased serum levels of rufinamide are observed when it is coadministered with phenytoin, phenobarbital, primidone, carbamazepine, and vigabatrin [7, 8] . In addition, rufinamide decreases the plasma concentrations of carbamazepine and lamotrigine by 7% to 13%, and increases plasma levels of phenobarbital by 8% to 13% and phenytoin by 7% to 21% [6, 7] .
The half-life of rufinamide is relatively short, 6 to 10 hours, and plasma rufinamide concentrations rise slowly-time to maximum plasma concentration (T max ) is approximately 4 to 6 hours-which minimizes fluctuations in plasma concentrations with twice-daily (BID) dosing [7] . Steady-state (SS) exposure to rufinamide, whether described as peak plasma concentration (C max , SS ) or area under the curve for 12-hour dosing (AUC 0-12,SS ), increases at a rate that is less than dose-proportional. Rufinamide is absorbed well when taken with food, which increases C max and AUC, but has no effect on T max [7] .
In the United States, the Food and Drug Administration (FDA)-recommended starting dose for rufinamide in pediatric patients (1 to <17 years of age) with LGS is approximately 10 mg/kg, administered in two equally divided doses. This dose may be increased by 10 mg/kg every other day, up to a maximum dose of 45 mg/kg, not to exceed 3200 mg/day [6] . For adults ≥17 years, treatment should be initiated at 400 to 800 mg/day administered in two equally divided doses, with dose increases of 400 to 800 mg every other day up to a maximum dose of 3200 mg/day [6] .
The European Medicines Agency (EMA) recommends an initial dose of 200 mg daily in children M a n u s c r i p t
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≥4 years old and <30 kg not receiving valproate; the dose may be increased by 200 mg/day as frequently as every 2 days, to a maximum dose of 1000 mg/day [9] . An initial dose of 400 mg/day is recommended for adults, adolescents, and children ≥4 years of age (≥30 kg), with 400 mg/day dose increases, as frequently as every 2 days, up to a maximum daily dose based on body weight as follows: 1800 mg/day for patients weighing 30.0-50.0 kg, 2400 mg/day for those weighing 50.1-70.0 kg, and 3200 mg/day for those weighing ≥70.1 kg [9] . The US and EMA labels both recommend lower starting doses for pediatric patients simultaneously receiving valproate, and the FDA also recommends a lower starting dose in adult patients receiving valproate [6, 9] .
Rufinamide's efficacy in LGS was demonstrated in a pivotal Phase III double-blind, placebo-
controlled trial and open-label extension (OLE) study [10, 11] . The use of rufinamide to treat patients with LGS in clinical practice has also been described, providing additional data on more flexible dosing schedules and outcomes. Here, real-world and clinical data will be considered with regard to dosing/titration versus AE patterns, concomitant AED use, and dosing for both pediatric and adult patients with LGS to provide insight into best clinical practices.
METHODS AND PATIENTS

Phase III Pivotal Trial and Open-Label Extension
The Phase III double-blind, placebo-controlled pivotal trial (core study) was 84 days in duration, and involved 138 patients with LGS, 4-30 years old (median 12 years), who were randomized to receive either rufinamide (N=74) or placebo (N=64) [11] . The long-term OLE of the double-M a n u s c r i p t
Rufinamide Dosing Considerations Manuscript FINAL -Confidential 8 blind study involved 124 patients who participated for a median duration of 432 days (range 10-1149 days) [10] .
Study designs for the core and extension studies have been previously described. Eligibility criteria for the core study required a history of multiple seizure types, including atypical absence seizures and tonic-atonic ("drop attack") seizures, having ≥90 seizures in the preceding month, EEG evidence of a pattern of slow spike-and-wave complexes, and use of 1 to 3 concomitant fixed-dose AEDs at baseline [11] . After a 28-day baseline period, patients entered a 14-day titration period, followed by a 70-day maintenance period, for a total double-blind study period of 84 days [11] . Patients were given a starting dose of approximately 10 mg/kg/day, with a dosing target of 45 mg/kg/day or the maximum daily dose by patient weight ( Table 1) , whichever was less [11] . Dose titration was undertaken according to the schedule shown in Table 1 .
The OLE study titration schedule for patients who received placebo during the core study and were switched to rufinamide was similar to that of the core study. These patients initiated rufinamide treatment at 10 mg/kg/day and increased to approximately 25-60 mg/kg/day in 1-2 weeks [10] . Dosing of rufinamide for all patients could be modified at the investigator's discretion to a range of approximately 10-60 mg/kg/day, given as BID or thrice-daily (TID) doses [10] .
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The literature search to develop background for this article was based on articles in English found on PubMed up to June 2015. The primary search terms were "rufinamide," AND "pediatrics," OR "adults," OR "titration," OR "dose," AND "Lennox-Gastaut syndrome."
Additional information from treatment in other epilepsy syndromes was garnered using the search terms: "rufinamide," AND "pediatrics," OR "adults," OR "titration," OR "dose," NOT "Lennox-Gastaut syndrome." Only articles in English and human studies were included. Articles of interest were initially reviewed as abstracts, and examined in their entirety when deemed appropriate. Pharmacokinetic simulations and review articles were excluded, but reference lists from key review articles were reviewed for additional sources. Eighteen articles were selected based on this methodology, a summary of which may be seen in Table 2 .
RESULTS
Dose
Core Study: The mean dose after the 7-to 14-day titration period was approximately 1700 mg/day (median 1800 mg/day) for both the rufinamide and placebo groups. The target dose (45 mg/kg/day) was reached by 87.8% (n=65) of patients receiving rufinamide; 50 (76.9%) achieved the target dose on a 7-day schedule, while the remaining 15 (23.1%) followed a 14-day titration period [11] . Twenty-six of 65 patients who reached the target dose were aged ≥4 to <12 years, and 39 were ≥12 years of age. Of the 9 rufinamide patients who did not reach the target dose, 5
were aged 4-11 years, and 4 were aged 13-23 years. The mean (and median) dose remained consistent throughout the maintenance period of the core study.
M a n u s c r i p t p=0.002) [11] .
OLE Study: Because duration of the OLE varied among the 43 centers in 9 countries where it was conducted, efficacy was measured across 6 patient cohorts, based on the minimum duration of their rufinamide treatment: 6, 12, 18, 24, 30 or 36 months. Compared to baseline, the median total seizure frequency was reduced throughout the OLE study for every cohort [10] . Reduction in seizure frequency continued for patients previously on rufinamide during the core study, while patients who received placebo during the core study and switched to rufinamide during the OLE experienced a 22% median reduction in total seizures after 2 weeks of rufinamide treatment [10] .
Tonic-atonic seizure frequency followed the overall pattern and was reduced at every time point for all cohorts in the OLE [10] .
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Effect of Titration and Dose on AEs
Core Study: The most common AEs, occurring in at least 10% of patients in either the rufinamide or placebo groups during the core study, are shown in Table 3 . Serious AEs (SAEs)
and AEs leading to discontinuation that occurred in the first 21 days of rufinamide treatment during the core and OLE studies are presented in OLE Study: Seventeen patients in the OLE experienced SAEs; 10 of these patients received placebo during the core study and therefore had to convert/titrate to rufinamide at the beginning of the OLE. Of these 10 patients, 3 reported SAEs during the first 2 weeks of rufinamide treatment. Twelve patients withdrew from the OLE due to AEs, 9 of whom received placebo during the core study. Of these 9 patients, 6 had an AE that occurred during the first 20 days of initiating rufinamide. As was the case in the Core study, no clinically meaningful changes in ECG were observed during the OLE. Core Study: In the core study, a one-compartment PK model demonstrated a significant relationship between rufinamide exposure and both total seizure frequency and tonic-atonic seizure frequency, an effect that was not modified by use of any of the concomitant AEDs. Also in the core study, the finding that rufinamide-treated patients had a larger decrease in median total seizure frequency compared to placebo remained statistically significant for patients who received 2 or 3 AEDs (p=0.047 and p=0.015, respectively).
OLE Study: While the majority of patients (75%) remained on the same number of concomitant AEDs over the course of the OLE, the daily dose of concomitant AEDs was reduced in 47.7% of patients during the first 6 months of the OLE. Moreover, dose reductions were seen through Month 36 of the OLE (Table 6 ) [10] . [12] . Compared to other studies of rufinamide in LGS, the target dose is notably higher and the rate of titration is faster in the Phase III/OLE and Ohtsuka et al studies [12] . And while the rate of AEs is generally higher in the Phase III and OLE studies compared to other studies, the efficacy rate is generally consistent. These data give credence to the notion that a "low and slow" approach to dosing and titration is associated with consistent treatment outcomes and increased tolerability.
REAL-WORLD CLINICAL DATA
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Studies of Rufinamide in LGS
DISCUSSION
Phase III/OLE
The rate of titration in both the core and OLE studies may be considered rapid. Although most patients were able to tolerate this rate of titration, a minority of patients experienced AEs during the first 3 weeks that challenged their ability to achieve and/or maintain the target dose in the 7-day (and 14-day) time frame. A subset of patients was unable to reach the target dose in the brief titration period or withdrew from the study due to AEs during or shortly after the titration period.
AEs that resulted in 3 of the 6 withdrawals in the core study occurred within 18 days of initiating treatment with rufinamide. Severe AEs were reported in 9 patients in the core study; most of With regard to concomitant AED use, there is no evidence that the agents used by patients in either the core or OLE study reduced or increased the plasma concentrations of rufinamide to the point of clinical significance. This is consistent with some other studies of patients with LGS receiving rufinamide in addition to concomitant AEDs, although a significant effect of valproate, particularly in young children, has been reported in several studies [13] [14] [15] . The effect of valproate on the PK of rufinamide may be clinically relevant in extreme circumstances (eg, in children on high doses of both compounds) and may lead to clinically significant elevation of rufinamide levels (by 70% or more). However, there is little safety concern in this regard, as the combination appears equally safe and well tolerated. Additional analysis of rufinamide exposure with concomitant valproate in smaller patients using an alternative model suggested smaller increases in rufinamide plasma concentrations than previously predicted. Using this model, which may be more appropriate based on rufinamide's mechanism of action, the patients with the highest rufinamide exposure experienced an increase of approximately 30% with concomitant valproate [15] .
Rufinamide-treated patients had a larger decrease in median total seizure frequency compared to placebo, a difference that remained statistically significant for patients who received 2 or 3
AEDs. It is possible, however, that tolerability issues associated with use of multiple M a n u s c r i p t 
Real-World Clinical Data
Differences in target dosing between pediatric and adult patients with LGS have been previously reviewed [16] and may be seen in several of the more recent studies noted above, specifically, studies by Coppola et al, Lee et al, Cusmai et al, and Kessler et al. [13, [17] [18] [19] . Target doses for children weighing ≤30 kg ranged from 800 mg/day to 1000 mg/day (except for those receiving valproate in the Cusmai study, who were given a target dose of 600 mg/day). ( Table 2) In each of these studies, the rate of AEs was notably lower than the rates seen in the Phase III and OLE studies [10, 11, 13, [17] [18] [19] .
Marchand et al conducted clinical trial simulations using a population PK model and applying outcomes from clinical trials in patients with LGS and in those with partial and generalized seizures [15] . These simulations produced a recommended daily maximum dose of 1000 mg/day in patients weighing <30 kg, and a maximum of 600 mg/day for those receiving valproate [15] .
In the Vendrame 2011 case series, the highest dose of rufinamide with efficacy and tolerability was 800 mg/day [20] . Higher doses of 1000 mg/day in patients <30 kg and 3200 mg/day in patients >30 kg (mean dose of 54.5 mg/kg/day in patients not receiving concomitant valproate)
have also been used safely in the treatment of LGS [13] . and adults, adjunctive rufinamide at a dose of 3200 mg/day was also shown to be effective and safe in controlling partial seizures [21] . Dahlin and Ohman observed a significantly higher clearance of rufinamide in patients aged 0 to 4.9 years not on valproate compared to children 5 to 10.9 years and those 11 to 17.9 years of age. The youngest group also experienced a significant reduction in clearance if they were receiving valproate, but no such effect was seen in the two older age groups [22] . The mean rufinamide plasma concentrations of 29.6 µmol/L and 17.2 µmol/L reported by Dahlin and Ohtsuka, respectively, are within the range observed in the Phase III core study [11, 12, 22] . [Glauser_2008, p6; Ohtsuka_2014, p7; Dahlin_2012, p4]
Other authors have described their clinical experiences in treating children with rufinamide at altered doses. Hsieh and Thiele describe treating a heterogeneous population of children with epilepsy (not LGS-specific) at an initial dose of 5-10 mg/kg/day in two separate doses, increasing by 5-10 mg/kg/day every 5-7 days, to a maintenance dose of 45-50 mg/kg/day, with good tolerability and no compromise in efficacy [23] . Vendrame et al used variable titration schedules in their report of treating pediatric patients with rufinamide. When titrating at a rate of 10 mg/kg per week, the authors note that patients were successfully treated, with a mild sideeffect profile [24] .
Clinical experiences with rufinamide treatment of patients with epilepsy syndromes other than
LGS provide further insights on dosing and titration. Grosso et al showed that in patients with infantile spasms, rufinamide titration was slightly more rapid (over an 18-to 21-day period), highlighting the importance of clinical response to the drug [25] . In a retrospective study of A c c e p t e d M a n u s c r i p t
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The pattern of AEs that occurred during the rufinamide titration phase of the Phase III and OLE studies, and which subsided during the maintenance phase, is consistent with the pattern of AEs reported in other studies. As may be seen in the real-world studies reviewed in LGS and non-
LGS populations (Table 2) , the tolerability of rufinamide in clinical practice appears to be improved by using a lower starting dose and slower titration schedule [8] . These recent data supplement previous findings that a "low and slow" dosing strategy is often adopted in realworld practice, in contrast to clinical trial data. Such dosing strategies do not appear to compromise efficacy and may provide improvements in tolerability [16] . Slow titration also permits assessment of clinical efficacy of rufinamide at low dosages, and treatment response has been observed at doses as low as 10-15 mg/kg/day [8] . Lee et al observed efficacy rates comparable to those in the Phase III and OLE studies, with a mean rufinamide dose of 35 mg/kg/day and lower rates of AEs [18] . For patients who require rapid efficacy-as in cases of severe or frequent seizures-rufinamide can be titrated at a fast rate. If necessary, titration in 2 to 3 days to a target dose of up to 20 mg/kg/day can be done, albeit with a commensurate increase in risk of AEs [8] .
This analysis is limited by the lack of data on the treatment of adults with rufinamide, although several studies included small numbers of adult patients in their study populations. Coppola et al and Ohtsuka et al reported no significant difference in the responder rates by age group, while
Cusmai et al found a significantly better response in patients aged 8-18 years relative to other M a n u s c r i p t [27] . [McMurray_2016, p37, p39, col1] Rufinamide was generally well tolerated in this population, and had a side effect profile similar to the overall population [27] .
[McMurray_2016, p39, col2] A study of adult and adolescent patients with partial seizures indicate that adverse events were more frequent during the titration than maintenance phases of treatment when rufinamide was initiated at a dose at 800 mg/day and increased to 3200 mg/day over 7 days [28] . M a n u s c r i p t 
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